Siggy, a mental health startup founded by Jonathan Sabbagh of Journey Clinical and Edvard Engesæth of Nurx, secured $6 million in pre-seed funding to develop an AI-powered service that collects patient histories and tracks progress between visits with licensed clinicians.
- Raised $6 million in pre-seed led by Village Global
- Uses AI and wearable tech for mental health tracking
- Co-founders have prior success with Journey Clinical and Nurx
What happened
Siggy, a new mental health startup, announced it has raised $6 million in pre-seed funding led by Village Global. The New York-based company was founded by Jonathan Sabbagh and Edvard Engesæth, who previously built Journey Clinical and Nurx, respectively—both companies aimed at expanding patient access to non-traditional healthcare services.
The startup has begun accepting paying patients ahead of a public launch and plans to use this funding to expand its team of clinicians and engineers, enhance its AI-driven software, and address regulatory requirements. The company’s technology collects patient histories and monitors their health status between appointments using AI and data from wearable devices.
Why it matters
Siggy addresses a critical gap in mental healthcare where therapists and medication-prescribing clinicians often operate separately, leaving patients with limited opportunities to discuss symptom changes or medication side effects outside infrequent appointments. By using AI-driven daily check-ins and wearable data integration, Siggy offers clinicians a richer, more continuous view of a patient's condition.
This approach allows for earlier identification of negative trends in mood, sleep, or physical health, potentially leading to more timely interventions. Patients receive a 'Siggy Score' based on their reported symptoms and wearable data, which both the patient and clinician can monitor to guide treatment decisions.
What to watch next
Siggy’s immediate focus is on refining its technology through real-world patient data and expanding its team to scale operations. The company plans to validate its service in early patient trials before launching publicly and intends to facilitate information sharing with other healthcare providers and loved ones as a planned future feature.
While Siggy does not prescribe controlled substances or function as a crisis service, its integration of AI with licensed clinician oversight could pave new pathways for mental health management beyond traditional office visits. How well it can navigate regulatory frameworks and patient adoption will be key factors in its success.